AnalystsInsight

Daniel Brennan (TD Cowen): Analyst Track Record and Price‑Target Accuracy

How often Daniel Brennan’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1,237 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Daniel Brennan ranks #133 of 1,000 analysts in Exent’s scoring (5.0★).
  • 51.3% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 89 days; 46.8% of calls were up 12 months later.
  • Most‑covered stocks: NTRA, TEM, TMO, WGS.

Daniel Brennan’s track record at a glance

Daniel Brennan of TD Cowen ranks #133 of the 1,000 analysts Exent scores, with a 5.0★ rating and a focus on healthcare. Over a 7‑year lookback, 51.3% of Daniel’s price targets were reached, 1.1 points below the 52.4% average across all analysts.

MetricDaniel BrennanAll analysts
Price‑target hit rate51.3%52.4%
Median days to hit target89 days91 days
Calls up after 12 months46.8%64.0%
Median 12‑month return of calls−3.5%+13.4%
Hit rate, last 2 years52.3%—
Average worst drop after a call−29.5%—
Ratings in the sample1,237—
Stocks covered40—

How fast price targets were reached

Time to reach the targetDaniel Brennan
Under 30 days25.8%
30–90 days25.4%
90–180 days24.2%
Over 180 days24.6%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Daniel Brennan covers most

StockRatings in the sample
NTRA22
TEM21
TMO18
WGS18
A17
TXG17
CAI17
RVTY16

In the past year Daniel’s ratings were 71% Buy, 29% Hold and 0% Sell.

Recent ratings (shown with a 30-day delay)

DateStockActionRatingPrice target
Aug 27, 2026ARated: BuyBuy$180.00
Aug 18, 2026FRNMInitiated Coverage: BuyBuy$17.00
Aug 14, 2026GRALReiterated: BuyBuy$88.00
Aug 13, 2026MDXHReiterated: BuyBuy$1.00
Aug 12, 2026SERAReiterated: BuyBuy$0.00
Aug 11, 2026QTRXRated: HoldHold$3.00
Aug 7, 2026RVTYRated: BuyBuy$130.00
Aug 7, 2026WATUpgraded: BuyBuy$475.00
Aug 7, 2026NTRARated: BuyBuy$340.00
Aug 6, 2026BDSXReiterated: BuyBuy$30.00
Aug 6, 2026PACBReiterated: BuyBuy$3.00
Aug 6, 2026GRALReiterated: BuyBuy$88.00
  • Aug 27, 2026
    Stock
    A
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $180.00
  • Aug 18, 2026
    Stock
    FRNM
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $17.00
  • Aug 14, 2026
    Stock
    GRAL
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $88.00
  • Aug 13, 2026
    Stock
    MDXH
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $1.00
  • Aug 12, 2026
    Stock
    SERA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 11, 2026
    Stock
    QTRX
    Action
    Rated: Hold
    Rating
    Hold
    Price target
    $3.00
  • Aug 7, 2026
    Stock
    RVTY
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $130.00
  • Aug 7, 2026
    Stock
    WAT
    Action
    Upgraded: Buy
    Rating
    Buy
    Price target
    $475.00
  • Aug 7, 2026
    Stock
    NTRA
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $340.00
  • Aug 6, 2026
    Stock
    BDSX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $30.00
  • Aug 6, 2026
    Stock
    PACB
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $3.00
  • Aug 6, 2026
    Stock
    GRAL
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $88.00

Live ratings from Daniel Brennan and the other top‑ranked analysts, and the stocks where they agree, are in Exent Stocks Radar.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Stocks Radar shows Daniel Brennan’s live ratings and those of the other top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Daniel Brennan ranks #133 of 1,000 with a 5.0★ rating. 51.3% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 46.8% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Daniel Brennan’s success rate is 59.8% by the ranking source and 51.3% by Exent’s price-target hit-rate backtest, with a median of 89 days to reach a target.

Daniel Brennan (TD Cowen) covers 40 stocks, mostly in healthcare. The most frequently rated are NTRA, TEM, TMO, WGS, A.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.